Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

7074.3;4 LSPP-LS

Titre du projet

Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Titre du projet anglais

Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins
Résumé des résultats (Abstract) (Anglais)	Plants have been shown to be an economically viable alternative for the production of therapeutic recombinant proteins. A major obstacle is the non-human glycosylation pattern introduced by the plant N-glycosylation machinery, which can influence circulatory half-life, immunogenicity and biological activity. GlycArt Biotechnology¿s glycoengineering methods for mammalian cells will now be adapted to plants in collaboration with Dr. Kallio¿s group to engineer the plant cell glycosylation machinery to produce recombinant therapeutic glycoproteins with human-like carbohydrates.

Catégorie

Texte

Description succincte
(Anglais)

Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Résumé des résultats (Abstract)
(Anglais)

Plants have been shown to be an economically viable alternative for the production of therapeutic recombinant proteins. A major obstacle is the non-human glycosylation pattern introduced by the plant N-glycosylation machinery, which can influence circulatory half-life, immunogenicity and biological activity. GlycArt Biotechnology¿s glycoengineering methods for mammalian cells will now be adapted to plants in collaboration with Dr. Kallio¿s group to engineer the plant cell glycosylation machinery to produce recombinant therapeutic glycoproteins with human-like carbohydrates.